December 22, 2011

Everolimus in Refractory Testicular Germ Cell Cancer

Share this content:
Everolimus in Refractory Testicular Germ Cell Cancer
 
Sponsors and Collaborators
National Cancer Institute, Slovakia
 
Contact
Michal Mego, Ass.prof
+421259378 ext 366
misomego@nou.sk
 
Daniela Svetlovska, PhD
+421259378 ext 592
 
Principal Investigators
Jozef Mardiak, Prof
National Cancer Institute (NCI)
 
Michal Mego, Ass.prof.
National Cancer Institute, Slovakia
 
ClinicalTrials.gov Identifier
NCT01466231
Recommended for you

Related Resources

News
You must be a registered member of Cancer Therapy Advisor to post a comment.
Click here to login   |  Click here to register

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs